Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	1.53B
Revenue (ttm)	384.10M
Net Income (ttm)	-9.07M
Shares Out	72.20M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	46.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,162
Open	20.73
Previous Close	20.82
Day's Range	20.41 - 21.55
52-Week Range	15.52 - 28.15
Beta	0.35
Analysts	Strong Buy
Price Target	36.60 (+72.56%)
Earnings Date	Oct 29, 2024

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of gia...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 297
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Financial Performance

In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.

Analyst Forecast

According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $36.6, which is an increase of 72.56% from the latest price.

Price Target

$36.6

(72.56% upside)

Analyst Consensus: Strong Buy